These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35239184)

  • 41. Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.
    Tsujikawa LM; Kharenko OA; Stotz SC; Rakai BD; Sarsons CD; Gilham D; Wasiak S; Fu L; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
    Biomed Pharmacother; 2022 Aug; 152():113230. PubMed ID: 35687908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and Synthesis of a Highly Selective and
    Preston A; Atkinson S; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Gray JRJ; Jones EJ; Lindon M; Michon AM; Mitchell DJ; Prinjha RK; Rianjongdee F; Rioja I; Seal J; Taylor S; Wall I; Watson RJ; Woolven J; Demont EH
    J Med Chem; 2020 Sep; 63(17):9070-9092. PubMed ID: 32691591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
    Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
    Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets.
    Qian H; Zhu M; Tan X; Zhang Y; Liu X; Yang L
    Cell Death Discov; 2023 Dec; 9(1):470. PubMed ID: 38135679
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
    Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E
    Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors.
    Aylott HE; Atkinson SJ; Bamborough P; Bassil A; Chung CW; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Messenger C; Mitchell D; Phillipou A; Preston A; Prinjha RK; Rianjongdee F; Rioja I; Seal JT; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2021 Mar; 64(6):3249-3281. PubMed ID: 33662213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural and biochemical insights into purine-based drug molecules in hBRD2 delineate a unique binding mode opening new vistas in the design of inhibitors of the BET family.
    Arole AH; Deshmukh P; Sridhar A; Mathur S; Mahalingaswamy M; Subramanya H; Dalavaikodihalli Nanjaiah N; Padmanabhan B
    Acta Crystallogr D Struct Biol; 2023 Aug; 79(Pt 8):758-774. PubMed ID: 37432115
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bromodomain Interactions with Acetylated Histone 4 Peptides in the BRD4 Tandem Domain: Effects on Domain Dynamics and Internal Flexibility.
    Wernersson S; Bobby R; Flavell L; Milbradt AG; Holdgate GA; Embrey KJ; Akke M
    Biochemistry; 2022 Nov; 61(21):2303-2318. PubMed ID: 36215732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and Evaluation of [
    Wang Y; Wang Y; Xu Y; Tocci D; Wang C
    ACS Omega; 2024 Aug; 9(34):36177-36184. PubMed ID: 39220497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain.
    Bai P; Yan L; Bagdasarian FA; Wilks MQ; Wey HY; Wang C
    Chem Commun (Camb); 2022 Aug; 58(69):9654-9657. PubMed ID: 35943085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BET bromodomain proteins are required for glioblastoma cell proliferation.
    Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
    Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
    Chen D; Lu T; Yan Z; Lu W; Zhou F; Lyu X; Xu B; Jiang H; Chen K; Luo C; Zhao Y
    Eur J Med Chem; 2019 Nov; 182():111633. PubMed ID: 31461688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.
    Rianjongdee F; Atkinson SJ; Chung CW; Grandi P; Gray JRJ; Kaushansky LJ; Medeiros P; Messenger C; Phillipou A; Preston A; Prinjha RK; Rioja I; Satz AL; Taylor S; Wall ID; Watson RJ; Yao G; Demont EH
    J Med Chem; 2021 Aug; 64(15):10806-10833. PubMed ID: 34251219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Binding selectivity of inhibitors toward the first over the second bromodomain of BRD4: theoretical insights from free energy calculations and multiple short molecular dynamics simulations.
    Wang Y; Wu S; Wang L; Yang Z; Zhao J; Zhang L
    RSC Adv; 2020 Dec; 11(2):745-759. PubMed ID: 35423696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation.
    Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D
    Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.
    Long J; Li B; Rodriguez-Blanco J; Pastori C; Volmar CH; Wahlestedt C; Capobianco A; Bai F; Pei XH; Ayad NG; Robbins DJ
    J Biol Chem; 2014 Dec; 289(51):35494-502. PubMed ID: 25355313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
    Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
    Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
    Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
    Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.